Refractory Chronic Cough
Jul 21, 2026
Novartis Secures FDA Traditional Approval for Fabhalta in Primary IgAN; GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough; Merck Secures FDA Approval for LIPFENDRA; Innovent Reports Positive Phase II Results for Soficinib in Vitiligo; Lilly Signs Deal to Acquire AtaiBeckley for Mental Health Therapies
Novartis Wins FDA Traditional Approval for Fabhalta to Treat Primary IgAN Novartis announced that the US Food and Drug Administration (FDA) has granted traditional approval to Fabhalta (iptacopan) for slowing the progression of kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) wh...
Read More...
Dec 12, 2025
Limited Refractory Chronic Cough Treatment Landscape: LYFNUA Approval Restricted to Europe and Japan
Refractory chronic cough (RCC) is characterized by ongoing coughing that persists even after comprehensive evaluation and appropriate management of all identifiable underlying causes, pointing to an underlying neurogenic cough hypersensitivity. It is clinically distinct from other forms of chronic cough, and diagno...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
